iBio, Inc. (IBIO) stock
IBIONasdaqPharmaceutical PreparationsFiscal year ends June 30
$0.75+0.04 (+5.86%)
Close on Nov 17, 2026Market cap $48.11MP/E –Yield –
iBio total assets
Total assets on the balance sheet at the end of each period.
iBio's total assets was $88.65M at Sep 30, 2026. For fiscal 2026 it was $99.11M, up 327.5% from the year before. Over ten years it grew 6.7% a year on average. The highest annual figure on record is $146.97M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $99.11M | +327.5% |
| FY2025 | Jun 30, 2025 | $23.19M | -19.3% |
| FY2024 | Jun 30, 2024 | $28.73M | -30.3% |
| FY2023 | Jun 30, 2023 | $41.21M | -58.5% |
| FY2022 | Jun 30, 2022 | $99.41M | -32.4% |
| FY2021 | Jun 30, 2021 | $146.97M | +56.0% |
| FY2020 | Jun 30, 2020 | $94.19M | +207.9% |
| FY2019 | Jun 30, 2019 | $30.59M | -29.0% |
| FY2018 | Jun 30, 2018 | $43.08M | +19.6% |
| FY2017 | Jun 30, 2017 | $36.01M | -30.2% |
| FY2016 | Jun 30, 2016 | $51.60M | +313.0% |
| FY2015 | Jun 30, 2015 | $12.49M | +92.4% |
| FY2014 | Jun 30, 2014 | $6.49M | -30.6% |
| FY2013 | Jun 30, 2013 | $9.35M | -4.2% |
| FY2012 | Jun 30, 2012 | $9.77M | +33.1% |
| FY2011 | Jun 30, 2011 | $7.34M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | $88.65M | +38.2% |
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $99.11M | +327.5% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $85.83M | +349.3% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $64.39M | +196.8% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $64.16M | +161.7% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $23.19M | -19.3% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $19.10M | -61.9% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $21.70M | -36.2% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $24.52M | -34.9% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $28.73M | -30.3% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $50.15M | +13.0% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $34.02M | -34.3% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $37.68M | -55.4% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $41.21M | -58.5% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $44.39M | -61.5% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $51.80M | -59.0% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $84.56M | -42.5% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $99.41M | -30.3% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $115.37M | -20.7% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $126.45M | +7.8% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $146.97M | +56.0% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $142.70M | +238.0% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $145.41M | +299.6% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $117.26M | +233.5% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $94.19M | +207.9% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $42.22M | +18.3% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $36.38M | -9.7% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $35.16M | -18.0% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $30.59M | -29.0% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $35.67M | +15.0% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $40.30M | +15.7% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $42.90M | +28.3% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $43.08M | +19.6% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $31.03M | -23.7% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $34.84M | -21.2% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $33.43M | -30.5% |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $36.01M | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $40.70M | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $44.19M | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | $48.09M | – |
See a number that looks wrong?